X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com//news-release/2024/03/14/2845976/0/en/Hyloris-Reports-Full-Year-Results-for-2023-Provides-Business-Outlook.html
https://www.globenewswire.com//news-release/2024/03/14/2845961/0/en/Communication-at-the-request-of-the-FSMA-on-the-transactions-with-Qliniq.html
https://www.globenewswire.com/news-release/2024/03/08/2842882/0/en/Hyloris-to-Report-2023-Full-Year-Results-on-14-March-2024.html
https://www.globenewswire.com//news-release/2024/02/14/2829330/0/en/Hyloris-Enrolls-First-Patient-in-Phase-3-Clinical-Trial-for-its-Proprietary-Mouth-Rinse-to-Control-Incidences-of-Bleeding-Related-to-Dental-Procedures.html
https://www.globenewswire.com/news-release/2024/01/30/2819574/0/en/Hyloris-and-Purna-Female-Healthcare-Announce-Positive-Results-from-Phase-2-Trial-in-Patients-with-Acute-Vulvovaginal-Candidiasis-VVC.html
https://www.globenewswire.com//news-release/2024/01/18/2811837/0/en/Hyloris-Broadens-Pipeline-with-new-Product-Candidate-for-Vulvar-Lichen-Sclerosus-VLS.html
https://www.globenewswire.com//news-release/2024/01/16/2810252/0/en/Orphan-Drug-Designation-Granted-to-PTX-252-by-U-S-FDA-for-the-Treatment-of-Acute-Myeloid-Leukaemia-AML.html
https://www.globenewswire.com/news-release/2023/12/26/2801123/0/en/Hyloris-Announces-Positive-Clinical-Study-Results-for-Valacyclovir-Oral-Suspension-HY-029.html
https://www.globenewswire.com//news-release/2023/12/21/2800249/0/en/Hyloris-Broadens-Pipeline-with-new-Product-Candidate-in-Burning-Mouth-Syndrome.html
https://www.globenewswire.com//news-release/2023/10/24/2765248/0/en/Hyloris-Announces-Out-Licensing-of-Atomoxetine-Oral-Liquid-in-Canada.html
Market Place
Share 
